BRIEF-FDA Approves KEYTRUDA® (pembrolizumab) And KEYTRUDA QLEX™ (Pembrolizumab And Berahyaluronidase Alfa-Pmph), Each With Padcev® (enfortumab vedotin-ejfv)

Reuters
Nov 22
BRIEF-FDA Approves KEYTRUDA® (pembrolizumab) And KEYTRUDA QLEX™ (Pembrolizumab And Berahyaluronidase Alfa-Pmph), Each With Padcev® (enfortumab vedotin-ejfv)

Nov 21 (Reuters) - Merck & Co Inc MRK.N:

  • FDA APPROVES KEYTRUDA® (PEMBROLIZUMAB) AND KEYTRUDA QLEX™ (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH), EACH WITH PADCEV® (ENFORTUMAB VEDOTIN-EJFV), AS PERIOPERATIVE TREATMENT FOR ADULTS WITH CISPLATIN-INELIGIBLE MUSCLE-INVASIVE BLADDER CANCER

Source text: ID:nBw46rHP9a

Further company coverage: MRK.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10